Alzheimer’s Therapeutics Market Trends, Size, Demand, Opportunities and Future Share 2034
Alzheimer’s Therapeutics Market Growth, Trends, Size- By Drug Class, By Distribution Channel, By Drug Name - Regional Outlook, Competitive Strategies and Segment Forecast to 2034
| Published: Dec-2022 | Report ID: HLCA2227 | Pages: 1 - 237 | Formats*: |
| Category : Healthcare | |||
Alzheimer’s Therapeutics Market Introduction and Overview
According to SPER Market Research, the Global Alzheimers Therapeutics Market is estimated to reach USD 39.46 billion by 2034 with a CAGR of 20.89%.
The report includes an in-depth analysis of the Global Alzheimers Therapeutics Market, including market size and trends, Interface mix, Applications, and supplier analysis. Alzheimers therapeutics focus on the treatment and management of Alzheimers disease, a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes. The market for these therapeutics is driven by the rising prevalence of Alzheimers due to aging populations worldwide, increasing awareness of early diagnosis, and significant investments in research and development for innovative treatments, including disease-modifying therapies and biologics. Advances in biomarkers and diagnostic tools also support market growth. However, challenges persist, such as the high cost and lengthy approval process for new drugs, limited treatment options that only manage symptoms rather than cure the disease, and the complex pathology of Alzheimers, which makes drug development difficult. Additionally, reimbursement issues and regulatory hurdles further hinder market expansion.
By Product Insights: Based on Product the market is divided into four segments: Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drug and Pipeline Drugs. The cholinesterase inhibitors segment had the highest revenue share in 2024, as it is the standard of care for Alzheimer's patients. The cholinesterase inhibitor Adlarity (donepezil hydrochloride), created by Corium Inc., was approved by the U.S. FDA in March 2022 to treat individuals suffering from severe dementia caused by Alzheimer's disease (AD). It was the fourth cholinesterase medication to be approved and introduced in the United States. It is a transdermal patch that is applied once a week and provides a consistent dose of donepezil. Cholinesterase inhibitors, NMDA receptor antagonists, combination medications, and pipeline medications are the product-based segments of the market.
By End User Insights: Based on End User the market is divided into three segments: Hospital Pharmacy, Retail Pharmacy and E-commerce. The hospital pharmacy sector led the market in 2024 as a result of an increase in hospitalizations brought on by an aging population and an increase in Alzheimer's patients. In the senior population, there are 518 hospitalizations per 1,000 Medicare beneficiaries with Alzheimer's or other dementias, compared to just 234 hospitalizations per 1,000 Medicare enrollees without these illnesses, according to the Alzheimer's Association report from 2022. In contrast to the prevalence of Alzheimer's disease, it is anticipated that the overall number of hospitalizations for AD patients will continue to be low.
By Regional Insights: In 2024, North America led the industry and is expected to expand significantly over the course of the forecast period. The market is expanding as a result of increased research into Alzheimer's disease treatment. The U.S. FDA designated lecanemab (BAN2401), an anti-amyloid beta protofibril antibody used to treat Alzheimer's disease, as a Breakthrough Therapy in June 2021. Eisai Co., Ltd. and Biogen made the announcement. Furthermore, it is anticipated that growing government financing and efforts would accelerate market expansion.
Market Competitive Landscape:
The market for Alzheimers Therapeutics is quite competitive. In order to increase the range of services and products they offer, companies in the Alzheimers Therapeutics market are working with regional players and going worldwide. Some of the prominent players in Global Alzheimers Therapeutics Market are AbbVie Inc., AC Immune, Adamas Pharmaceuticals Inc., Biogen, Daiichi Sankyo Company Limited, Eisai Co. Ltd., H. Lundbeck A/S, Johnson & Johnson Services Inc., Novartis AG, TauRx Pharmaceuticals Ltd.
Recent Developments:
- In January 2024, Eisai Co. Ltd. was granted approval in China to treat Alzheimer's patients with its humanized anti-soluble aggregated amyloid-beta (Aβ) monoclonal antibody LEQEMBI.
- In December 2023, AbbVie Inc. agreed to purchase Cerevel Therapeutics and its extensive neuroscience pipeline of preclinical and clinical-stage medicines with potential for a number of ailments, including mood disorders, Parkinsons disease (PD), and schizophrenia. In support of a possible Alzheimer's disease psychosis program, this purchase will comprise Emraclidine, a positive allosteric modulator (PAM) of the muscarinic M4 receptor that is presently undergoing a Phase 1 investigation in senior healthy volunteers.
- In October 2022, Cyclo Therapeutics Inc. declared the launch of its Phase 2b research for Trappsol Cyclo, a treatment for Alzheimer's disease that aims to lower tau and amyloid beta. The Institutional Review Board (IRB) gave its clearance to the study.
- In September 2022, Eisai Co. Ltd. and Biogen Inc. revealed encouraging preliminary findings from Eisai's global Phase 3 Clarity AD trial of lecanemab, an experimental antibody used to treat moderate amyloid beta-induced Alzheimer's disease and mild cognitive impairment.
- In March 2022, Eisai Co. Ltd. and Biogen Inc. widened their collaboration to create Alzheimer's disease treatments.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2021-2034 |
| Base year considered | 2024 |
| Forecast period | 2025-2034 |
| Segments covered | By Product, By End User. |
| Regions covered | North America, Latin America, Asia-Pacific, Europe, and Middle East & Africa. |
| Companies Covered | AbbVie Inc., AC Immune, Adamas Pharmaceuticals Inc., Biogen, Daiichi Sankyo Company Limited, Eisai Co. Ltd., H. Lundbeck A/S, Johnson & Johnson Services Inc., Novartis AG, TauRx Pharmaceuticals Ltd. and others. |
Key Topics Covered in the Report:
- Global Alzheimers Therapeutics Market Size (FY2021-FY2034)
- Overview of Global Alzheimers Therapeutics Market
- Segmentation of Global Alzheimers Therapeutics Market By Product (Cholinesterase inhibitors, NMDA Receptor Antagonist, Combination Drug and Pipeline Drugs)
- Segmentation of Global Alzheimers Therapeutics Market By End User (Hospital Pharmacy, Retail Pharmacy and E-commerce)
- Statistical Snap of Global Alzheimers Therapeutics Market
- Expansion Analysis of Global Alzheimers Therapeutics Market
- Problems and Obstacles in Global Alzheimers Therapeutics Market
- Competitive Landscape in the Global Alzheimers Therapeutics Market
- Details on Current Investment in Global Alzheimers Therapeutics Market
- Competitive Analysis of Global Alzheimers Therapeutics Market
- Prominent Players in the Global Alzheimers Therapeutics Market
- SWOT Analysis of Global Alzheimers Therapeutics Market
- Global Alzheimers Therapeutics Market Future Outlook and Projections (FY2025-FY2034)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPERs internal database2.1.4. Premium insight from KOLs
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities4.1.4. Challenges
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTERs Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global Alzheimers Therapeutics Market Manufacturing Base Distribution, Sales Area, Interface Type6.2. Mergers & Acquisitions, Partnerships, Interface Launch, and Collaboration in Global Alzheimers Therapeutics Market
7. Global Alzheimers Therapeutics Market, By Product (USD Million) 2021-2034
7.1. Cholinesterase inhibitors
7.1.1. Donepezil7.1.2. Galantamine7.1.3. Rivastigmine
7.2. NMDA Receptor Antagonist7.3. Combination Drug7.4. Pipeline Drugs
8. Global Alzheimers Therapeutics Market, By End User (USD Million) 2021-2034
8.1. Hospital Pharmacy8.2. Retail Pharmacy8.3. E-Commerce
9. Global Alzheimers Therapeutics Market, (USD Million) 2021-2034
9.1. Global Alzheimers Therapeutics Market Size and Market Share
10. Global Alzheimers Therapeutics Market, By Region, (USD Million) 2021-2034
10.1. Asia-Pacific
10.1.1. Australia10.1.2. China10.1.3. India10.1.4. Japan10.1.5. South Korea10.1.6. Rest of Asia-Pacific
10.2. Europe
10.2.1. France10.2.2. Germany10.2.3. Italy10.2.4. Spain10.2.5. United Kingdom10.2.6. Rest of Europe
10.3. Middle East and Africa
10.3.1. Kingdom of Saudi Arabia10.3.2. United Arab Emirates10.3.3. Qatar10.3.4. South Africa10.3.5. Egypt10.3.6. Morocco10.3.7. Nigeria10.3.8. Rest of Middle-East and Africa
10.4. North America
10.4.1. Canada10.4.2. Mexico10.4.3. United States
10.5. Latin America
10.5.1. Argentina10.5.2. Brazil10.5.3. Rest of Latin America
11. Company Profile
11.1. AbbVie Inc.
11.1.1. Company details11.1.2. Financial outlook11.1.3. Interface summary11.1.4. Recent developments
11.2. AC Immune
11.2.1. Company details11.2.2. Financial outlook11.2.3. Interface summary11.2.4. Recent developments
11.3. Adamas Pharmaceuticals Inc.
11.3.1. Company details11.3.2. Financial outlook11.3.3. Interface summary11.3.4. Recent developments
11.4. Biogen
11.4.1. Company details11.4.2. Financial outlook11.4.3. Interface summary11.4.4. Recent developments
11.5. Daichi Sankyo Company Limited
11.5.1. Company details11.5.2. Financial outlook11.5.3. Interface summary11.5.4. Recent developments
11.6. Eisai Co. Ltd.
11.6.1. Company details11.6.2. Financial outlook11.6.3. Interface summary11.6.4. Recent developments
11.7. H. Lundbeck A/S
11.7.1. Company details11.7.2. Financial outlook11.7.3. Interface summary11.7.4. Recent developments
11.8. Johnson & Johnson Services Inc.
11.8.1. Company details11.8.2. Financial outlook11.8.3. Interface summary11.8.4. Recent developments
11.9. Novartis AG
11.9.1. Company details11.9.2. Financial outlook11.9.3. Interface summary11.9.4. Recent developments
11.10. TauRx Pharmaceuticals Ltd.
11.10.1. Company details11.10.2. Financial outlook11.10.3. Interface summary11.10.4. Recent developments
12. Conclusion
13. List of Abbreviations
14. Reference Links
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
Alzheimer’s Therapeutics Market is projected to reach USD 39.46 billion by 2034, growing at a CAGR of 39.46% during the forecast period.
Alzheimer’s Therapeutics Market grew in Market size from 2025. The Market is expected to reach USD 39.46 billion by 2034, at a CAGR of 20.89% during the forecast period.
Alzheimer’s Therapeutics Market CAGR of 20.89% during the forecast period.
You can get the sample pages by clicking the link - Click Here
Alzheimer’s Therapeutics Market size is USD 39.46 billion from 2025 to 2034.
Alzheimer’s Therapeutics Market is covered By Product, By End User.
The North America is anticipated to have the highest Market share in the Alzheimer’s Therapeutics Market.
The key players in the Market include Companies Covered AbbVie Inc., AC Immune, Adamas Pharmaceuticals Inc., Biogen, Daiichi Sankyo Company Limited, Eisai Co. Ltd., H. Lundbeck A/S, Johnson & Johnson Services Inc., Novartis AG, TauRx Pharmaceuticals Ltd. and others.
Alzheimers therapeutics focus on the treatment and management of Alzheimers disease, a progressive neurodegenerative disorder characterized by memory loss, cognitive decline, and behavioral changes.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
